Document:

EX-10.1

 Exhibit 10.1 

AMENDED AND RESTATED CHANGE OF CONTROL/SEVERANCE AGREEMENT 

This AMENDED AND RESTATED CHANGE OF CONTROL/SEVERANCE AGREEMENT (this “Agreement”), dated as of January 31, 2017 is entered
into by and between PAREXEL International Corporation (together with all subsidiaries or affiliates hereinafter referred to as the “Company”) and Mark A. Goldberg (the “Executive”). 

WHEREAS, the Executive remains a senior executive of the Company and continues to be expected to make major contributions to the Company; 

WHEREAS, the Company desires continuity of management; 

WHEREAS, the Executive is willing to continue to render services to the Company subject to the conditions set forth in this Agreement; and

 WHEREAS, the Executive and the Company have entered into an Amended and Restated Change of Control/Severance Agreement (the “Current
Agreement”), dated as of October 31, 2008, and both parties desire to amend and restate the Current Agreement as set forth herein. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the
Executive agree that the Current Agreement is hereby amended and restated in its entirety as set forth in this Agreement: 
 1.
Termination without Cause or for Good Reason. 
 If the Company terminates the Executive’s employment with the Company
without Cause (as such term is defined in Section 6 below) other than due to the Executive’s death or Disability (as such term is defined in Section 6 below), or the Executive terminates his employment with the Company for Good Reason
(as such term defined in Section 6 below), the Company shall provide the Executive with the Accrued Compensation (as such term is defined in Section 6 below), and, subject to the terms and conditions set forth in this Agreement, with the
following severance benefits: 
 (a) The Company shall pay to the Executive as severance pay an amount (net of any required withholding)
equal to the sum of (i) twenty-four (24) months of the Executive’s monthly base salary (at the highest monthly base salary rate in effect for the Executive in the twelve month period prior to the termination of his employment) (the
“Base Salary Severance Component”), (ii) an amount (the “Benefit Component”) equal to two (2) times the sum of the value of all benefits the Executive receives (excluding medical and dental benefits, and life and
accident insurance) immediately prior to the Executive’s last date of employment with the Company (the “Termination Date”) provided, however, that any such sum shall be reduced by an amount equal to (x) the amount of any benefit
payment made in advance to the Executive for the year in which the Termination Date occurs (the “Pre-Paid Amount”), less (y) the result obtained by multiplying (A) the quotient obtained by dividing the Pre-Paid Amount by 365, by
(B) the number of calendar days in the year of Termination up to and including the Termination Date, and (iii) subject to certification of the achievement of the applicable performance goal(s) under

 
the annual incentive award plan1 following the end of the applicable performance period in accordance with Section 162(m) of the Internal
Revenue Code of 1986, as amended, (the “Code”) (the “Bonus Certification”), two (2) times the greater of (x) the target amount of the Executive’s annual bonus under the Company’s Management Incentive Plan, as
amended, and any successor bonus plan thereto, the “MIP”) for the fiscal year in which the Termination Date occurs or (y) the amount of the annual bonus paid to the Executive pursuant to the MIP for the fiscal year immediately prior
to that in which the Termination Date occurs (the “Bonus Severance Component”). The Base Salary Severance Component and the Benefit Component shall be paid to the Executive in equal bi-monthly installments in accordance with the
Company’s regular payroll practices for a twenty-four month period beginning on the Company’s first regular payroll date after the Release Effective Date (as such term is defined in Section 6 below). The Bonus Severance Component
shall be paid to the Executive in equal bi-monthly installments in accordance with the Company’s regular payroll practices for a twenty-four month period beginning on the Company’s first regular payroll date after the later of (i) the
date of the Bonus Certification or (ii) the Release Effective Date. 
 (b) In addition: 

 

	 	(1)	subject to the terms and conditions provided for by the law known as “COBRA”, and subject to the Executive’s timely election of COBRA and the Executive’s copayment of premium amounts at the active
employee rate, the Company shall pay its share of premium payments as from time to time in effect for active employees for group medical and dental insurance through the earliest of (1) eighteen (18) months following the Executive’s
Termination Date, (2) the date the Executive becomes eligible through new employment for medical and/or dental benefits substantially comparable to the benefits provided under the corresponding Company plan (“Comparable Medical and Dental
Benefits”), or (3) the date Executive becomes ineligible for COBRA benefits (as applicable, the “COBRA Contribution Period”); provided, however, that such Company-paid premiums may be recorded as additional income pursuant to
Section 6041 of the Code, and not entitled to any tax qualified treatment to the extent necessary to comply with or avoid the discriminatory treatment prohibited by the Patient Protection and Affordable Care Act of 2010 and the Health Care and
Education Reconciliation Act of 2010 or Section 105(h) of the Code. The Executive agrees to give prompt written notice of any subsequent employment he obtains during the COBRA Contribution Period that results in his eligibility for Comparable
Medical and Dental benefits. Notwithstanding the foregoing, if the Executive has not become eligible through new employment for Comparable Medical and/or Dental Benefits prior to the date the COBRA Contribution Period 

 

	1 	 Solely for illustrative purposes, the current target under the PBP is positive adjusted operating income.

  
 2 

	 	
ends, the Company will, until the earlier of the date which is twenty-four months following the Executive’s Termination Date and the date the Executive becomes eligible through new
employment for Comparable Medical and/or Dental Benefits, continue to pay its share of premium payments, as from time to time in effect for active employees; provided however that if the Executive is not eligible to continue on the Company’s
group medical and/or dental plans following the end of the COBRA Contribution Period, the Company shall pay to the Executive an amount equal to six (6) times its then-current share of monthly premium payments, which payment shall be made in a
single lump sum within ten (10) days following the end of the COBRA Contribution Period. If the Company determines, in its discretion, that it cannot pay its share of premium payments as described in this Section 1(b)(1) without income tax
consequences to the Executive, the Company may instead provide an additional monthly amount of severance payment to the Executive sufficient to cover the employer share of the premium for the Executive’s group medical and dental insurance
coverage for the period described above in this Section 1(b)(1) (but in all events for no longer than twenty-four (24) months), together with an amount sufficient to pay any taxes on such additional severance payments. 

 

	 	(2)	Further, the Company shall, until the earlier of twenty-four (24) months following the Executive’s Termination Date or the date the Executive becomes eligible through new employment for life and/or accident
insurance substantially comparable to such benefits as provided to him by the Company (“Comparable Life and/or Accident Insurance”), provide the Executive with Comparable Life and/or Accident Insurance or reimburse the Executive for the
costs of his obtaining Comparable Life and/or Accident Insurance. The Executive agrees to give prompt written notice of any subsequent employment he obtains prior to the date that is twenty-four (24) months following his Termination Date that
results in his eligibility for Comparable Life and/or Accident Insurance. 

 (c) All unvested equity awards held by the
Executive as of the Termination Date shall remain outstanding and shall automatically become 100% vested, exercisable, and issuable and any forfeiture restrictions thereon shall immediately lapse on the Release Effective Date, subject to the timely
execution and nonrevocation of the Release Agreement as described in Section 6. Notwithstanding the foregoing sentence, if the Executive holds a performance-based equity award that vests based upon the achievement of performance metrics and the
Executive’s termination of employment occurs prior to the last day of the applicable performance period for such award, then such award shall remain outstanding and shall be deemed earned (and vest) when (and only to the extent that) the
Compensation Committee certifies that the relevant performance metrics have been achieved following the end of the 

  
 3 

 
applicable performance period, as if the Executive had remained employed through the end of the performance period. 

(d) Any amounts and benefits set forth in this Section 1 shall be reduced by any and all other severance or other amounts or benefits
with the exception of qualified or nonqualified retirement or deferred compensation benefits paid or payable to the Executive as a result of the termination of his employment for any reason, other than pursuant to this Agreement. 

2. Termination Without Cause or for Good Reason Within Six Months Prior to or Twenty-Four Months following a Change of
Control. 
 Notwithstanding the provisions of Section 1 above, if, within six (6) months prior to a Change of
Control (provided that substantive discussions had already commenced that ultimately resulted in the Change of Control) or twenty-four (24) months following a Change of Control, the Company terminates the Executive’s employment without
Cause other than due to the Executive’s death or Disability or the Executive terminates his employment with the Company for Good Reason, the Company shall, in addition to the Accrued Compensation, and subject to the terms and conditions set
forth in this Agreement, provide the Executive with the following Change of Control severance benefits: 
 (a) The Company shall pay to the
Executive, within thirty (30) calendar days following the Release Effective Date, a lump sum amount (net of any required withholding) equal to two (2) times the sum of: (i) his annualized base salary (at the highest annualized base
salary rate in effect for the Executive in the twelve month period prior to the termination of his employment), (ii) an amount equal to the sum of the value of all benefits the Executive receives (excluding medical and dental benefits, and life
and accident insurance) immediately prior to the Termination Date, provided, however, that any such sum shall be reduced by an amount equal to (x) the Pre-Paid Amount (as defined in Section 1(a) above), less (y) the result obtained by
multiplying (A) the quotient obtained by dividing the Pre-Paid Amount by 365, by (B) the number of calendar days in the year of Termination up to and including the Termination Date, and (iii) the greater of (x) the target amount
of the Executive’s annual bonus under the MIP for the fiscal year in which the Executive’s employment is terminated or (y) the amount of the annual bonus paid to the Executive pursuant to the MIP for the fiscal year immediately prior
to that in which the Termination Date occurs. 
 (b) The Company shall provide the Executive with the benefits set forth in Section 1(b)
above, subject to the same terms, conditions, and limitations as described therein; provided, however, that any payment made pursuant to the last sentence of Section 1(b)(1) shall be paid in a single-lump sum within thirty (30) calendar
days following the Release Effective Date. 
 (c) All unvested equity awards held by the Executive as of the Termination Date shall remain
outstanding and shall automatically become 100% vested, exercisable, and issuable and any forfeiture restrictions thereon shall immediately lapse on the Release Effective Date, subject to the timely execution and nonrevocation of the Release
Agreement as described in Section 6. For purposes of the foregoing sentence, in the event the Executive holds a 

  
 4 

 
performance-based equity award that vests based upon the achievement of performance metrics and the Executive’s termination of employment occurs prior to the last day of the applicable
performance period for such award, then such award be deemed earned as to the “target” level of performance. 
 (d) The Company
shall provide the Executive with up to thirty-five thousand dollars ($35,000.00) of outplacement services through the placement agency of the Executive’s choice, to be used on or before the earlier of the date that is twelve (12) months
following the Release Effective Date or the date on which the Executive secures other employment (with payment for such services to be provided by the Company directly to the outplacement agency). 

(e) For the avoidance of doubt, any payments and benefits to which the Executive becomes entitled under this Section 2 shall be reduced in
an amount and/or by the duration, as applicable, equal to the payments and/or benefits the Executive received pursuant to Section 1 prior to the effective date of the Change of Control, if any, and the Executive shall not be entitled to receive
any further payments or benefits pursuant to Section 1. Further, any amounts and benefits set forth in this Section 2 shall be reduced by any and all other severance or other amounts or benefits with the exception of qualified or
nonqualified retirement or deferred compensation benefits paid or payable to the Executive as a result of the termination of his employment for any reason, other than pursuant to this Agreement. 

3. Termination Due to the Executive’s Death or Disability, or by the Company for Cause or by the Executive without Good
Reason.  
 In the event of any termination of the Executive’s employment that is not pursuant to Section 1 or 2 of
this Agreement, including without limitation the Executive’s termination by the Company for Cause, the Executive’s resignation without Good Reason, or termination due to the Executive’s death or Disability, the Executive shall be
entitled only to the Accrued Compensation, and shall not be entitled to any other payments or benefits hereunder, regardless of when such termination occurs; provided, however, that in the event the Executive’s employment terminates due to his
death or Disability, all unvested equity awards held by the Executive as of the Termination Date shall (i) in the event of a termination as a result of the Executive’s death, automatically become 100% vested, exercisable, and issuable and
any forfeiture restrictions thereon shall immediately lapse on the Termination Date and (ii) in the event of a termination as a result of the Executive’s Disability, remain outstanding and shall automatically become 100% vested,
exercisable, and issuable and any forfeiture restrictions thereon shall immediately lapse on the Release Effective Date, subject to the timely execution and nonrevocation of the Release Agreement as described in Section 6. For purposes of the
foregoing, in the event the Executive holds a performance-based equity award that vests based upon the achievement of performance metrics and the Executive’s termination of employment due to death or Disability occurs prior to the last day of
the applicable performance period for such award, then such award shall, as of the last day of the applicable performance period, be earned to the extent it would have been earned pursuant to the terms of such award had the Executive remained
employed through the last day of the applicable performance period and automatically become vested, exercisable, and issuable, and any forfeiture restrictions thereon shall immediately lapse, as applicable, as of such last day of the applicable
performance period. 

  
 5 

 4. Distributions. The following rules shall apply with respect to distribution of
the payments and benefits, if any, to be provided to the Executive under this Agreement: 
 (a) It is intended that each installment
of the payments and benefits provided under this Agreement shall be treated as a separate “payment” for purposes of Section 409A of the U.S. Internal Revenue Code of 1986, as amended, and the guidance issued thereunder (“Section
409A”). Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A; 

(b) If, as of the date of the “separation from service” of the Executive from the Company, the Executive is not a “specified
employee” (each within the meaning of Section 409A), then each installment of the payments and benefits shall be made on the dates and terms set forth in this Agreement; and 

(c) If, as of the date of the “separation from service” of the Executive from the Company, the Executive is a “specified
employee” (each, for purposes of this Agreement, within the meaning of Section 409A), then: 
  

	 	(1)	Each installment of the payments and benefits that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the
short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation § 1.409A-1(b)(4) to the maximum extent permissible under Section 409A; and

  

	 	(2)	 Each installment of the payments and benefits due under this Agreement described in Section 4(c)(1) above
and that would, absent this subsection, be paid within the six-month period following the Executive’s “separation from service” from the Company shall not be paid until the date that is six months and one day after such separation
from service (or, if earlier, the death of the Executive), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following the
Executive’s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any
installment of payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation
§ 1.409A-1(b)(9)(iii) 

  
 6 

	 	
(relating to separation pay upon an involuntary separation from service) or Treasury Regulation § 1.409A-1(b)(9)(iv) (relating to reimbursements and certain other separation payments). Such
payments shall bear interest at an annual rate equal to the prime rate as set forth in the Eastern edition of the Wall Street Journal on the Date of Termination, from the Date of Termination to the date of payment. Any installments that qualify for
the exception under Treasury Regulation § 1.409A-1(b)(9)(iii) must be paid no later than the last day of the second taxable year of the Executive following the taxable year of the Executive in which the separation from service occurs.

 (d) All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the
requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during
Executive’s lifetime (or during a shorter period specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year,
(iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or
exchange for any other benefit. 
 5. Amended and Restated Key Employee Agreement. 

As a condition of this Agreement and the effectiveness hereof, the Executive shall, at the same time he executes this Agreement, also execute
and deliver to the Company the Amended and Restated Key Employee Agreement attached hereto as Exhibit A. 
 6. General.

 (a) The Executive will not be eligible for, nor shall he have a right to receive, any payments or benefits from the Company following
the Termination Date other than as set forth in this Agreement. Except as otherwise described in this Agreement, each equity award held by the Executive upon a termination of employment shall be treated in accordance with the applicable award
agreement and/or plan document governing such award. 
 (b) For purposes of this Agreement, the following terms shall have the meanings set
forth below: 
  

	 	(1)	 “Accrued Compensation” shall mean: any accrued base salary earned by the Executive as of the date of
termination, any accrued but unused PTO, and any amounts for reimbursement of any appropriate business expenses incurred by the Executive in connection with the performance of his duties for the Company, all to the extent unpaid on the Termination
Date. The Executive’s 

  
 7 

	 	
entitlement to any other compensation or benefit under any plan of the Company shall be governed by and determined in accordance with the terms of such plans, except as otherwise specified in
this Agreement. 

  

	 	(2)	“Change of Control” shall mean: The closing of: (i) a merger, consolidation, liquidation or reorganization of the Company into or with another Company or other legal person, after which merger,
consolidation, liquidation or reorganization the capital stock of the Company outstanding prior to consummation of the transaction is not converted into or exchanged for or does not represent more than 50% of the aggregate voting power of the
surviving or resulting entity; (ii) the direct or indirect acquisition by any person (including a “person” as such term is used in Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of more than 50%
of the voting capital stock of the Company, in a single or series of related transactions; or (iii) the sale, exchange, or transfer of all or substantially all of the Company’s assets (other than a sale, exchange or transfer to one or more
entities where the stockholders of the Company immediately before such sale, exchange or transfer retain, directly or indirectly, at least a majority of the beneficial interest in the voting stock of the entities to which the assets were
transferred). Notwithstanding the foregoing, for any payments or benefits hereunder that are subject to Section 409A, the Change of Control must constitute a “change in control event” within the meaning of Treasury Regulation
Section 1.409A-3(i)(5)(i). 

  

	 	(3)	“Cause” shall mean: (i) the commission by the Executive of a felony, either in connection with the performance of his obligations to the Company or which adversely affects the Executive’s ability to
perform such obligations; (ii) the Executive’s gross negligence, breach of fiduciary duty or breach of any confidentiality, non-competition or developments agreement in favor of the Company; or (iii) the commission by the Executive of
an act of fraud or embezzlement or other acts in intentional disregard of the Company which result in loss, damage or injury to the Company, whether directly or indirectly. 

 

	 	(4)	 “Good Reason” shall mean: That the Executive has complied with the “Good Reason Process” as
defined below, following the occurrence of one or more of the following events without the Executive’s written consent: (i) the assignment to the Executive of any duties inconsistent in any adverse, material respect with his position,
authority, duties or responsibilities or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities; (ii) a material

  
 8 

	 	
reduction in the aggregate of the Executive’s base compensation; (iii) a change by the Company in the location at which the Executive performs the Executive’s principal duties for
the Company to a new location that is both (X) outside a radius of forty (40) miles from the Executive’s principal residence immediately prior to the Change of Control and (Y) more than thirty (30) miles from the location at
which the Executive performed the Executive’s principal duties for the Company on the date of this Agreement; or a requirement by the Company that the Executive travel on Company business to a substantially greater extent than required
immediately prior to the date of this Agreement; or (iv) a failure by the Company to obtain the agreement of the successor referenced in Section 6(d). “Good Reason Process” shall mean that (A) the Executive reasonably
determines in good faith that one of the foregoing “Good Reason” conditions has occurred; (B) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within ninety (90) days of the first
occurrence of such condition; (C) the Executive cooperates in good faith with the Company’s efforts, for a period not less than thirty (30) days following such notice (the “Cure Period”), to remedy the condition;
(D) notwithstanding such efforts, the Good Reason condition continues to exist; and (E) the Executive terminates his employment within two (2) years of the first occurrence of such condition. If the Company cures the Good Reason
condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

  

	 	(5)	“Disability” shall mean: the Executive’s becoming permanently and totally disabled (within the meaning of Section 22(e)(3) of the Code). 

(c) The Executive shall not be required to mitigate the amount of any payment provided for in this Agreement by seeking other employment or
otherwise, nor shall any profits, income, earnings or other benefits from any source whatsoever create any mitigation, offset, reduction or any other obligation on the part of the Executive, except as otherwise expressly set forth herein. 

(d) Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit of the Company and any successor
(whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) of the Company; provided, however, that as a condition of closing any transaction which results in a Change of Control, the Company shall
obtain the written agreement of any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) of the Company to be bound by the provisions of this Agreement as if such successor were the Company and for
purposes of this Agreement, any such successor of the Company shall be deemed to be the “Company” for all purposes. 

  
 9 

 (e) Nothing in this Agreement shall create any obligation on the part of the Company or any other
person to continue the employment of the Executive. By Employee’s execution of this Agreement, Employee acknowledges and agrees that Employee’s employment with the Company is “at will.” 

(f) Nothing herein shall affect the Executive’s obligations under any key employee, non-competition, confidentiality, option or similar
agreement between the Company and the Executive currently in effect or which may be entered into in the future, including without limitation the Amended and Restated Key Employee Agreement. 

(g) The Company’s obligation to make any payments or provide any benefits under this Agreement (except the Accrued Compensation) is
contingent upon the Executive’s entering into and complying with a separation and release of claims agreement in the form attached hereto as Exhibit B (the “Release Agreement”), which Release Agreement must be signed by the Executive
and any applicable revocation period with respect thereto must have expired by the sixtieth (60th) day following the Termination Date (such
60th day, the “Release Effective Date”). Notwithstanding the foregoing, if the 60th day following the Termination Date occurs in the
calendar year following calendar year in which the Termination Date occurs, then the Executive shall not commence receiving any payments or benefits under this Agreement (except the Accrued Compensation) earlier than January 1 of such
subsequent calendar year. In addition, to remain eligible to receive any payments or benefits pursuant to this Agreement, the Executive must comply with all post-employment obligations, including without limitation those in the Amended and Restated
Key Employee Agreement. Further, the Company’s obligation to make any payments or provide any benefits hereunder (except the Accrued Compensation) is contingent upon the Executive, if applicable, having tendered his resignation from the
Company’s Board of Directors and all offices the Executive holds in the Company (and any other boards on which the Executive serves or offices that he holds at the request of the Company), effective as of the date of the Executive’s
termination. Finally, if the Executive has already entered into the Release Agreement as a result of a termination described in Section 1 of this Agreement at the time he becomes eligible to receive payments and benefits under Section 2 of
this Agreement, the Company’s obligation to make any additional payments, provide any additional benefits or change the time at which any payments (in accordance with the terms of Section 2) are made, is contingent upon the
Executive’s entering into and complying with an additional release of claims that shall release the Released Parties (as defined in the Release Agreement) from any and all claims by the Executive that may have arisen following his execution of
the Release Agreement, including without limitation any claims relating to a Change of Control (the “Additional Release”). 
 (h)
This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. This Agreement constitutes the entire Agreement between the Executive and the Company concerning the subject matter hereof and
supersedes any prior negotiations, understandings or agreements concerning the subject matter hereof, whether oral or written, and may be amended or rescinded only upon the written consent of the Company and the Executive. The invalidity or
unenforceability of any provision of this Agreement shall not affect the other provisions of this Agreement and this Agreement shall be construed and reformed to the fullest extent possible. The Executive may not assign any of his rights or
obligations under this Agreement; the rights and obligations of the Company under this 

  
 10 

 
Agreement shall inure to the benefit of, and shall be binding upon, the successors and assigns of the Company. This Agreement may be executed in any number of counterparts, all of which taken
together shall constitute one and the same instrument. 
 (i) This Agreement is intended to comply with the provisions of Section 409A
and shall, to the extent practicable, be construed in accordance therewith. Terms defined in the Agreement shall have the meanings given such terms under Section 409A if and to the extent required in order to comply with Section 409A.
Notwithstanding the foregoing, to the extent that the Agreement or any payment or benefit hereunder shall be deemed not to comply with Section 409A, then neither the Company, the Board of Directors nor its or their designees or agents shall be
liable to the Executive or any other person for any actions, decisions or determinations made in good faith. 
 IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be executed as of the date first written above. 
  

			
	 The Company:
  

PAREXEL INTERNATIONAL CORPORATION

		
	By:	 	/s/ Josef H. von Rickenbach
	Name:	 	 /s/ Josef H. von Rickenbach

	Title:	 	 Chairman and Chief Executive Officer

  
  

			
	The Executive:
		
	Signature:	 	/s/ Mark A. Goldberg
	Printed Name:	 	Mark A. Goldberg

  
 11Exhibit 10.1

 

COMMON STOCK
PURCHASE AGREEMENT

 

COMMON STOCK PURCHASE AGREEMENT
(the “Agreement”), dated as of February 3, 2017 by and between IMMUNE PHARMACEUTICALS INC., a Delaware
corporation (the “Company”), and HLHW IV, LLC, a Delaware limited liability company (the “Buyer”). Capitalized
terms used herein and not otherwise defined herein are defined in Section 10 hereof.

 

WHEREAS: 

 

Subject to the terms and conditions set
forth in this Agreement, the Company wishes to sell to the Buyer, and the Buyer wishes to buy from the Company, up to Three Million
Fifty Seven Thousand Nine Hundred Dollars ($3,057,900) of the Company’s common stock, par value $0.0001 per share (the “Common
Stock”). The shares of Common Stock to be purchased hereunder are referred to herein as the “Purchase Shares.”

 

NOW THEREFORE, the Company and the
Buyer hereby agree as follows:

 

	 	1.	PURCHASE OF COMMON STOCK.

 

Subject to the terms and conditions set
forth in this Agreement, the Company has the right to sell to the Buyer, and the Buyer has the obligation to purchase from the
Company, Purchase Shares as follows:

 

(a) Commencement of Purchases of Common
Stock.  On the day following the filing of the Form 8-K as described in Section 4 herein, but not later than February
3, 2017 (“Effective Date”), the Company shall deliver such number of shares of Common Stock or a combination
thereto, at the election of Buyer, representing a dollar amount equal to $230,167 representing the payment of the Commitment Shares
(as defined in Section 4(e)) based on a per share price equal to the lowest intraday bid price on the Effective Date (each such
tranche of the purchase, the “Initial Purchase” and each such tranche of the initial Purchase Shares are referred
to herein as “Initial Purchase Shares”). Such Initial Purchase Shares shall be validly issued and fully paid
and non-assessable. Thereafter, the purchase and sale of additional Purchase Shares hereunder shall occur from time to time upon
written notices by the Company to the Buyer on the terms and conditions as set forth herein following the satisfaction of the conditions
(the “Commencement”) as set forth in Sections 6 and 7 below (the date of satisfaction of such conditions, the
“Commencement Date”).

 

(b) The Company’s Right to Require
Regular Purchases. Subject to item (d) below and the terms and conditions of this Agreement, on any given Business Day
after the Commencement Date, the Company shall have the right but not the obligation to direct the Buyer by its delivery to the
Buyer of a Purchase Notice from time to time, and the Buyer thereupon shall have the obligation, to buy the number of Purchase
Shares specified in such notice, up to 500,000 Purchase Shares, on such Business Day (as long as such notice is delivered on or
before 9:00 a.m. Eastern time on such Business Day), unless delivery of a Purchase Notice is waived by Buyer in its sole discretion
(each such purchase, a “Regular Purchase”) at the Purchase Price on the Purchase Date; however, in no event
shall the Purchase Amount of a Regular Purchase exceed Two Hundred and Fifty Thousand Dollars ($250,000) per Business Day, unless
the Buyer and the Company mutually agree. The Company and the Buyer may mutually agree to increase the number of Purchase
Shares that may be sold pursuant to a Regular Purchase to as much as an additional 2,000,000 Purchase Shares per Business Day.
The Company may deliver additional Purchase Notices to the Buyer from time to time so long as the most recent purchase has been
completed. The share amounts in this Section 1(b) shall be appropriately adjusted for any reorganization, recapitalization,
non-cash dividend, stock split, reverse stock split or other similar transaction. Unless waived by the Buyer, the Company is prohibited
from requesting Regular and/or Additional Purchases for five (5) Business Days from the Commencement Date.

 

(c) Additional Purchases. Subject
to item (d) below and the terms and conditions of this Agreement, in addition to purchases of Purchase Shares as described in Section
1(b) above, with one Business Day’s prior written notice, the Company shall also have the right but not the obligation to
direct the Buyer by delivery to the Buyer of an Additional Purchase Notice from time to time, and the Buyer thereupon shall have
the obligation, to buy up to an additional 30% of the trading volume of the Common Stock for the next Business Day (each such purchase,
an “Additional Purchase”) at the Additional Purchase Price. The Company may deliver an Additional Purchase
Notice to the Buyer on or before 9:00 a.m. Eastern time on a date on which (i) the Company also submitted a Purchase Notice for
a Regular Purchase of at least 200,000 Purchase Shares to the Buyer and (ii) the Closing Bid Price is higher than $0.10. The
share amount in the prior sentence shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend,
stock split, reverse stock split or other similar transaction.  Upon completion of each Additional Purchase, the Buyer
shall submit to the Company a confirmation of the Additional Purchase in form and substance reasonably acceptable to the Company. The
Company may deliver Additional Purchase Notices to the Buyer from time to time so long as the most recent purchase has been completed.

 

    1 

     

    

 

(d) Limitation on Purchases. In
the event the Company delivers a Purchase Notice or Additional Purchase Notice to Buyer for more than thirty percent (30%) of the
average of the five (5) previous Business Days dollar volume of the Common Stock on the Trading Market on which the Common Stock
is then listed or quoted as reported by Bloomberg L.P. based on a Trading Day from 9:30 AM (NYC time) to 4:02 PM (NYC time) for
the nearest preceding Business Day (“Volume Limitation”), the Buyer, in its sole discretion, may either accept
or reject the Purchase Notice or Additional Purchase Notice, in whole or in part. Furthermore, provided the Company can deliver
the Purchase Shares or Additional Purchase Shares via DWAC, the Company shall be obligated to require Regular Purchases and/or
Additional Purchases for an aggregate number of Purchase Shares and/or Additional Purchase Shares representing a dollar value of
an aggregate amount of not less than $1,000,000 per month, subject to the Volume Limitation. Upon failure of the Company to comply
with its obligation to sell to Buyer a number of Purchase Shares with an aggregate value of at least $1,000,000, the Company will
pay to the Buyer as liquidated damages the sum of $50,000 for each thirty (30) day period such failure continues. If for any reason
the Transfer Agent does not timely deliver the Shares via DWAC, Buyer, in its sole discretion, may then cancel the Purchase and
the Company will be required to pay Buyer as liquidated damages, and not as a penalty the sum of $5,000. If the Buyer elects not
to cancel the Purchase Notice and/or an Additional Purchase Notice, the Company will pay to the Buyer as liquidated damages the
sum of $5,000 per day until the Transfer Agent delivers the Purchase Shares to Buyer. In the event the Principal Market is closed
or there is no trading in the Common Stock or trading has been halted for any reason whatsoever, Buyer, in its sole discretion,
may reject a part of or all of the Purchase Notice or Additional Purchase Notice.

 

(e) Payment for Purchase Shares. For
each Regular Purchase, the Buyer shall pay to the Company an amount equal to the Purchase Amount minus any amounts or credits whatsoever
due to Buyer, as full payment for such Purchase Shares via wire transfer of immediately available funds on or before the fourth
Business Day following delivery of the Purchase Shares to Buyer. For each Additional Purchase, the Buyer shall pay to the
Company an amount equal to the Additional Purchase Amount minus any amounts or credits whatsoever due to Buyer, as full payment
for such Additional Purchase Shares via wire transfer of immediately available funds on or before the fourth Business Day following
the delivery of Additional Purchase Shares to Buyer. All payments made under this Agreement shall be made in lawful money
of the United States of America via wire transfer of immediately available funds to such account as the Company may from time to
time designate by written notice in accordance with the provisions of this Agreement. Whenever any amount expressed to be
due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the next succeeding
day that is a Business Day. Failure to deliver the Purchase Shares or Additional Purchase Shares within three Business Days of
the Purchase Date or Additional Purchase Date, the Company will pay Buyer as liquidated damages, and not as a penalty, five percent
(5%) of the value of the Common Stock based on the closing bid price of the Common stock for each such day until the Shares are
delivered to Buyer.

 

(f) Purchase Price Floor. The
Company and the Buyer shall not effect any sales under this Agreement on any Purchase Date where the Closing Bid Price is less
than the Floor Price, unless waived by Buyer. “Floor Price” means $0.10 per share of Common Stock, which
shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or
other similar transaction.

 

(g) Records of Purchases. The
Buyer and the Company shall each maintain records showing the remaining Available Amount at any given time and the dates and Purchase
Amounts for each purchase, or shall use such other method reasonably satisfactory to the Buyer and the Company to reconcile the
remaining Available Amount.

 

(h) Taxes. The Company shall
pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery of any shares of
Common Stock to the Buyer made under this Agreement.

 

(i) Compliance with Principal
Market Rules. Notwithstanding anything in this Agreement to the contrary, unless permitted by the applicable rules
and regulations of the Principal Market, the total number of shares of Common Stock that may be issued under this Agreement,
including the Commitment Fee (as defined in Section 4(e) hereof), shall not exceed the aggregate number of shares of Common
Stock which the Company may issue upon without breaching the Company’s obligations under the rules or regulations of
the Principal Market (the number of shares which may be issued without violating such rules and regulations, the
“Exchange Cap”). Notwithstanding the foregoing, such limitation shall not apply in the event that the
Company obtains the approval of its stockholders as required by the applicable rules of the Principal Market for issuances of
shares of Common Stock in excess of such amount The Exchange Cap shall be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction.  The Company
may, in its sole discretion, determine whether to obtain stockholder approval to issue more shares of Common Stock hereunder
than is permitted by the Exchange Cap if such issuance would require stockholder approval under the rules or regulations of
the Principal Market.

 

(j) Beneficial Ownership Limitation.
The Company shall not issue, and the Buyer shall not purchase any shares of Common Stock under this Agreement, if such shares proposed
to be issued and sold, when aggregated with all other shares of Common Stock then owned beneficially (as calculated pursuant to
Section 13(d) of the Securities Exchange Act of 1934, as amended (the “1934 Act”) and Rule 13d-3 promulgated
thereunder) by the Buyer and its affiliates would result in the beneficial ownership by the Buyer and its affiliates of more than
4.99% of the then issued and outstanding shares of Common Stock of the Company, unless waived in writing by Buyer.

 

    2 

     

    

 

	 	2.	BUYER’S REPRESENTATIONS AND WARRANTIES. 

 

The Buyer represents and warrants to the
Company that as of the date hereof and as of the Commencement Date:

 

(a) Investment Purpose. The
Buyer is entering into this Agreement and acquiring the Commitment Shares and the Purchase Shares (the Purchase Shares and the
Commitment Shares are collectively referred to herein as the “Securities”), for its own account for investment
only and not with a view towards, or for resale in connection with, the public sale or distribution thereof; provided however,
by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum or other specific
term.

 

(b) Accredited Investor Status. The
Buyer is an “accredited investor” as that term is defined in Rule 501(a)(3) of Regulation D under the 1933 Act.

 

(c) Information. The Buyer
has been furnished with all materials relating to the business, finances and operations of the Company and materials relating to
the offer and sale of the Securities that have been reasonably requested by the Buyer, including, without limitation, the SEC Documents
(as defined in Section 3(f) hereof). The Buyer understands that its investment in the Securities involves a high degree of
risk. The Buyer (i) is able to bear the economic risk of an investment in the Securities including a total loss, (ii) has
such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the proposed
investment in the Securities and (iii) has had an opportunity to ask questions of and receive answers from the officers of the
Company concerning the financial condition and business of the Company and other matters related to an investment in the Securities. Neither
such inquiries nor any other due diligence investigations conducted by the Buyer or its representatives shall modify, amend or
affect the Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The
Buyer has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with
respect to its acquisition of the Securities.

 

(d) No Governmental Review. The
Buyer understands that no United States federal or state agency or any other government or governmental agency has passed on or
made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor
have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(e) Organization. The Buyer is a
limited liability company duly organized and validly existing in good standing under the laws of the jurisdiction in which it is
organized, and has the requisite organizational power and authority to own its properties and to carry on its business as now being
conducted.

 

(f) Validity; Enforcement. This
Agreement has been duly and validly authorized, executed and delivered on behalf of the Buyer and is a valid and binding agreement
of the Buyer enforceable against the Buyer in accordance with its terms, subject as to enforceability to (i) general principles
of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to,
or affecting generally, the enforcement of applicable creditors’ rights and remedies and (ii) public policy underlying any
law, rule or regulation (including any federal or state securities law, rule or regulation) with regards to indemnification, contribution
or exculpation. The execution and delivery of the Transaction Documents (as defined in Section 3(b) hereof) by the Buyer and the
consummation by it of the transactions contemplated hereby and thereby do not conflict with the Buyer’s certificate of organization
or operating agreement or similar documents, and do not require further consent or authorization by the Buyer, its managers or
its members.

 

(g) Residency. The Buyer is
a resident of the State of Delaware.

 

(h) No Prior Short Selling. The
Buyer represents and warrants to the Company that at no time prior to the date of this Agreement has any of the Buyer, its agents,
representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i) “short sale”
(as such term is defined in Section 242.200 of Regulation SHO of the 1934 Act) of the Common Stock or (ii) hedging transaction,
which establishes a net short position with respect to the Common Stock.

 

    3 

     

    

 

	 	3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

 

Except as set forth herein or in the Schedules,
the Company represents and warrants to the Buyer that as of the date hereof and as of the Commencement Date:

 

(a) Organization and Qualification. The
Company and its “Subsidiaries” (which for purposes of this Agreement means any entity in which the Company,
directly or indirectly, owns more than 50% of the voting stock or capital stock or other similar equity interests) are corporations
or limited liability companies duly organized and validly existing in good standing under the laws of the jurisdiction in which
they are incorporated or organized, and have the requisite corporate or organizational power and authority to own their properties
and to carry on their business as now being conducted. Each of the Company and its Subsidiaries is duly qualified as a foreign
corporation or limited liability company to do business and is in good standing in every jurisdiction in which its ownership of
property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure
to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect. As used in
this Agreement, “Material Adverse Effect” means any material adverse effect on any of: (i) the business, properties,
assets, operations, results of operations or financial condition of the Company and its Subsidiaries, if any, taken as a whole,
or (ii) the authority or ability of the Company to perform its obligations under the Transaction Documents (as defined in Section
3(b) herein). The Company has no material Subsidiaries except as set forth on Schedule 3(a).

 

(b) Authorization; Enforcement; Validity. (i)
The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement, and
each of the other agreements entered into by the parties on the Commencement Date and attached hereto as exhibits to this Agreement
(collectively, the “Transaction Documents”), and to issue the Securities in accordance with the terms hereof
and thereof, (ii) the execution and delivery of the Transaction Documents by the Company and the consummation by it of the transactions
contemplated hereby and thereby, including without limitation, the issuance of the Commitment Shares and the reservation for issuance
and the issuance of the Purchase Shares and Additional Purchase Shares issuable under this Agreement, have been duly authorized
by the Company’s Board of Directors or duly authorized committee thereof, do not conflict with the Company’s Certificate
of Incorporation or Bylaws (as defined below), and do not require further consent or authorization by the Company, its Board of
Directors, except as set forth in this Agreement, or its stockholders, (iii) this Agreement has been, and each other Transaction
Document shall be on the Commencement Date, duly executed and delivered by the Company and (iv) this Agreement constitutes, and
each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid and binding obligations
of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by
(y) general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
relating to, or affecting generally, the enforcement of creditors’ rights and remedies and (z) public policy underlying
any law, rule or regulation (including any federal or state securities law, rule or regulation) with regards to indemnification,
contribution or exculpation. The Board of Directors of the Company or a duly authorized committee thereof has approved the
resolutions (the “Signing Resolutions”) substantially in the form as set forth as Exhibit B attached hereto
to authorize this Agreement and the transactions contemplated hereby. The Signing Resolutions are valid, in full force and
effect and have not been modified or supplemented in any material respect. The Company has delivered to the Buyer a true
and correct copy of the Signing Resolutions as approved by the Board of Directors of the Company.

 

(c) Capitalization. As of the
date hereof, the authorized capital stock of the Company consists of (i) 225,000,000 shares of Common Stock, par value $0.0001,
of which as of the date hereof, 173,476,315 shares are issued and outstanding, zero shares are held as treasury shares, 642,373
shares are reserved for future issuance pursuant to the Company’s 2015 Equity Incentive Plan, of which approximately 642,373
shares remain available for future option grants or stock awards, exercisable or exchangeable for, or convertible into, shares
of Common Stock, and (ii) zero shares of Series C or Series D preferred stock, with per share liquidation preferences set forth
on Schedule 3(c), of which as of the date hereof zero shares are issued and outstanding. All of such outstanding shares have
been, or upon issuance will be, validly issued and are fully paid and non-assessable. Except as disclosed in Schedule 3(c)
or the first sentence of this Section 3(c), (i) no shares of the Company’s capital stock are subject to preemptive rights
or any other similar rights or any liens or encumbrances suffered or permitted by the Company, (ii) there are no outstanding debt
securities of the Company or any of its Subsidiaries, (iii) there are no outstanding options, warrants, scrip, rights to subscribe
to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital
stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company
or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries
or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities
or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, (iv) there are no material agreements
or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of their securities
under the 1933 Act (except the Registration Rights Agreement), (v) there are no outstanding securities or instruments of the Company
or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any
of its Subsidiaries, (vi) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered
by the issuance of the Securities as described in this Agreement and (vii) the Company does not have any stock appreciation rights
or “phantom stock” plans or agreements or any similar plan or agreement. The Company has furnished or made available
to the Buyer true and correct copies of the Company’s Certificate of Incorporation, as amended and as in effect on the date
hereof (the “Certificate of Incorporation”), and the Company’s Bylaws, as amended and as in effect on
the date hereof (the “Bylaws”).

 

    4 

     

    

  

(d) Issuance of Securities. The
Commitment Shares and the Initial Purchase Shares have been duly authorized and, upon issuance in accordance with the terms hereof,
the Commitment Shares and the Initial Purchase Shares and Additional Purchase Shares shall be (i) validly issued, fully paid and
non-assessable and (ii) free from all taxes, liens and charges with respect to the issuance thereof. Upon issuance and payment
therefore in accordance with the terms and conditions of this Agreement, the Purchase Shares and Additional Purchase Shares shall
be validly issued, fully paid and non-assessable and free from all taxes, liens and charges with respect to the issue thereof,
with the holders being entitled to all rights accorded to a holder of Common Stock.

 

(e) No Conflicts. Except as
disclosed in Schedule 3(e), the execution, delivery and performance of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the reservation for issuance
and issuance of the Purchase Shares and Commitment Shares) will not (i) result in a violation of the Certificate of Incorporation,
any Certificate of Designations, Preferences and Rights of any outstanding series of preferred stock of the Company or the Bylaws
or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which the Company or any of its Subsidiaries is a party, or result, to the Company’s knowledge, in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and the rules and
regulations of the Principal Market applicable to the Company or any of its Subsidiaries) or by which any property or asset of
the Company or any of its Subsidiaries is bound or affected, except in the case of conflicts, defaults, terminations, amendments,
accelerations, cancellations and violations under clause (ii), which would not reasonably be expected to result in a Material Adverse
Effect. Except as disclosed in Schedule 3(e), neither the Company nor its Subsidiaries is in violation of any term of or in
default under its Certificate of Incorporation, any Certificate of Designation, Preferences and Rights of any outstanding series
of preferred stock of the Company or the Bylaws or their organizational charter or bylaws, respectively. Except as disclosed
in Schedule 3(e), neither the Company nor any of its Subsidiaries is in violation of any term of or is in default under any material
contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation
applicable to the Company or its Subsidiaries, except for possible violations, defaults, terminations or amendments that would
not reasonably be expected to have a Material Adverse Effect. The business of the Company and its Subsidiaries is not being
conducted, and shall not be conducted, in violation of any law, ordinance, or regulation of any governmental entity, except for
possible violations, the sanctions for which either individually or in the aggregate would not reasonably be expected to have a
Material Adverse Effect. Except as specifically contemplated by this Agreement, reporting obligations under the 1934 Act,
or as required under the 1933 Act or applicable state securities laws or the filing of a Listing of Additional Shares Notification
Form with the Principal Market, the Company is not required to obtain any consent, authorization or order of, or make any filing
or registration with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute,
deliver or perform any of its obligations under or contemplated by the Transaction Documents in accordance with the terms hereof
or thereof. Except as disclosed in Schedule 3(e) and for reporting obligations under the 1934 Act, all consents, authorizations,
orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence shall be obtained
or effected on or prior to the Commencement Date. Except as disclosed in Schedule 3(e), the Company is not subject to any
notices or actions from or to the Principal Market other than routine matters incident to listing on the Principal Market and not
involving a violation of the rules of the Principal Market. Except as disclosed in Schedule 3(e), to the Company’s knowledge,
the Principal Market has not commenced any delisting proceedings against the Company.

 

(f) SEC Documents; Financial Statements.
Except as disclosed in Schedule 3(f), since January 1, 2016, the Company has filed all reports, schedules, forms, statements and
other documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing
filed prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents incorporated
by reference therein being hereinafter referred to as the “SEC Documents”). As of their respective dates
(except as they have been correctly amended), the SEC Documents complied in all material respects with the requirements of the
1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents,
at the time they were filed with the SEC (except as they may have been properly amended), contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading. As of their respective dates (except as they have been
properly amended), the financial statements of the Company included in the SEC Documents complied as to form in all material respects
with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial
statements have been prepared in accordance with generally accepted accounting principles, consistently applied, during the periods
involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited
interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all
material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows
for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as
disclosed in Schedule 3(f) or routine correspondence, such as comment letters and notices of effectiveness in connection with previously
filed registration statements or periodic reports publicly available on EDGAR, to the Company’s knowledge, the Company or
any of its Subsidiaries are not presently the subject of any inquiry, investigation or action by the SEC.

 

    5 

     

    

 

(g) Absence of Certain Changes. Except
as disclosed in Schedule 3(g), since January 1, 2016, there has been no material adverse change in the business, properties, operations,
financial condition or results of operations of the Company or its Subsidiaries taken as a whole. For purposes of this Agreement,
neither a decrease in cash or cash equivalents or in the market price of the Common Stock nor losses incurred in the ordinary course
of the Company’s business shall be deemed or considered a material adverse change. The Company has not taken any steps,
and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor does the Company or any
of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy or insolvency
proceedings. The Company is financially solvent and is generally able to pay its debts as they become due.

 

(h) Absence of Litigation. Except
as disclosed in Schedule 3(h), to the Company’s knowledge, there is no action, suit, proceeding, inquiry or investigation
before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the
Company or any of its Subsidiaries, threatened against the Company, the Common Stock or any of the Company’s Subsidiaries
or any of the Company’s or the Company’s Subsidiaries’ officers or directors in their capacities as such, which
would reasonably be expected to have a Material Adverse Effect (each, an “Action”). A description of each
such Action, if any, is set forth in Schedule 3(h).

 

(i) Acknowledgment Regarding Buyer’s
Status. The Company acknowledges and agrees that the Buyer is acting solely in the capacity of arm’s length purchaser
with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges
that the Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the
Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Buyer or any of its representatives
or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental
to the Buyer’s purchase of the Securities. The Company further represents to the Buyer that the Company’s decision
to enter into the Transaction Documents has been based solely on the independent evaluation by the Company and its representatives
and advisors.

 

(j) Intellectual Property Rights. To
the Company’s knowledge, the Company and its Subsidiaries own or possess adequate rights or licenses to use all material
trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights (collectively, “Intellectual
Property”) necessary to conduct their respective businesses as now conducted, except as set forth in Schedule 3(j) or
to the extent that the failure to own, possess, license or otherwise hold adequate rights to use Intellectual Property would not,
individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in Schedule 3(j), to the Company’s
knowledge, none of the Company’s active and registered Intellectual Property have expired or terminated, or, by the terms
and conditions thereof, will expire or terminate within two years from the date of this Agreement, except as would not reasonably
be expected to have a Material Adverse Effect. The Company and its Subsidiaries do not have any knowledge of any infringement
by the Company or its Subsidiaries of any Intellectual Property of others and, except as set forth on Schedule 3(j), there is no
claim, action or proceeding being made or brought against, or to the Company’s knowledge, being threatened against, the Company
or its Subsidiaries regarding Intellectual Property, which could reasonably be expected to have a Material Adverse Effect.

 

(k) Environmental Laws. To
the Company’s knowledge, the Company and its Subsidiaries (i) are in material compliance with any and all applicable foreign,
federal, state and local laws and regulations relating to the protection of human health and safety or the environment and with
respect to hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii)
have received all material permits, licenses or other approvals required of them under applicable Environmental Laws to conduct
their respective businesses and (iii) are in material compliance with all terms and conditions of any such permit, license or approval,
except where, in each of the three foregoing clauses, the failure to so comply or receive such approvals would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect.

 

    6 

     

    

 

(l) Title. The Company and
its Subsidiaries have good and marketable title to all personal property owned by them that is material to the business of the
Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in
Schedule 3(l) or such as do not materially affect the value of such property and do not interfere with the use made and proposed
to be made of such property by the Company and any of its Subsidiaries or would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect. Any real property and facilities held under lease by the Company and any of
its Subsidiaries, to the Company’s knowledge, are held by them under valid, subsisting and enforceable leases with such exceptions
as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company
and its Subsidiaries.

 

(m) Insurance. The Company
and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as management of the Company believes to be reasonable and customary in the businesses in which the Company and its
Subsidiaries are engaged. To the Company’s knowledge, since January 1, 2016, neither the Company nor any such Subsidiary
has been refused any insurance coverage sought or applied for and neither the Company nor any such Subsidiary, to the Company’s
knowledge, will be unable to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material
Adverse Effect.

 

(n) Regulatory Permits. The
Company and its Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate federal, state
or foreign regulatory authorities necessary to conduct their respective businesses as currently conducted, and neither the Company
nor any such Subsidiary has received any written notice of proceedings relating to the revocation or modification of any such material
certificate, authorization or permit.

 

(o) Tax Status. The Company
and each of its Subsidiaries has made or filed all federal and state income and all other material tax returns, reports and declarations
required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its Subsidiaries
has set aside on its books reserves reasonably adequate for the payment of all unpaid and unreported taxes or filed valid extensions)
and has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations, except those being contested in good faith and has set aside on its books reserves reasonably
adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. To
the Company’s knowledge, there are no unpaid taxes in any material amount claimed to be due by the taxing authority of any
jurisdiction.

 

(p) Transactions With Affiliates. Except
as set forth on Schedule 3(p) and other than the grant or exercise of stock options or any other equity securities offered pursuant
to duly adopted stock or incentive compensation plans as disclosed on Schedule 3(c) or in the first sentence of Section 3(c),
none of the officers, directors or employees of the Company is presently a party to any transaction with the Company or any of
its Subsidiaries (other than for services as employees, officers and directors and reimbursement for expenses incurred on behalf
of the Company), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing
for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee
or, to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any
such employee has a material interest or is an officer, director, trustee or general partner.

 

(q) Application of Takeover Protections. The
Company and its board of directors have taken or will take prior to the Commencement Date all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the laws of the state of its incorporation,
other than Section 203 of the Delaware General Corporation Law, which is or could become applicable to the Buyer as a result of
the transactions contemplated by this Agreement, including, without limitation, the Company’s issuance of the Securities
and the Buyer’s ownership of the Securities.

 

(r) Registration Statement. The
Shelf Registration Statement (as defined in Section 4(a) hereof) has been declared effective by the SEC, and no stop order has
been issued or is pending or, to the knowledge of the Company, threatened by the SEC with respect thereto. As of the date
hereof, the Company has a dollar amount of securities registered and unsold under the Shelf Registration Statement, which is not
less than the sum of (i) the Available Amount and (ii) the market value of the Commitment Fee on the date hereof.

 

    7 

     

    

 

	 	4.	COVENANTS AND OTHER AGREEMENTS OF THE PARTIES. 

 

(a) Filing of Form 8-K and Prospectus
Supplement. The Company agrees that it shall, within one day of the Commencement Date, file a Current Report on Form 8-K
disclosing this Agreement and the transaction contemplated hereby. From and after the filing of the Form 8-K, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any Subsidiary, or any of their respective officers, directors, employees or agents in connection with the transactions
contemplated by the Transaction Documents. The Company shall file within two (2) Business Days from the date hereof a prospectus
supplement to the Company’s existing shelf registration statement on Form S-3 (File No. 333-198647, the “Shelf Registration
Statement”) covering the sale of the Commitment Shares and Purchase Shares (the “Prospectus Supplement”)
in accordance with the terms of the Registration Rights Agreement between the Company and the Buyer, dated as of the date hereof
(the “Registration Rights Agreement”). The Company shall use commercially reasonable efforts to keep the
Shelf Registration Statement and any New Registration Statement (as defined in the Registration Rights Agreement) effective pursuant
to Rule 415 promulgated under the 1933 Act and available for sales of all Securities to the Buyer until such time as (i) it no
longer qualifies to make sales under the Shelf Registration Statement (which shall be understood to include the inability of the
Company to immediately register sales of Securities to the Buyer under the Shelf Registration Statement or any New Registration
Statement pursuant to General Instruction I.B.6 of Form S-3), (ii) the date on which all the Securities have been sold under this
Agreement and no Available Amount remains thereunder, or (iii) the Agreement has been terminated. The Shelf Registration Statement
(including any amendments or supplements thereto and prospectuses or prospectus supplements, including the Prospectus Supplement,
contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading.

 

(b) Blue Sky. The Company shall
take such action, if any, as is reasonably necessary in order to obtain an exemption for or to qualify (i) the initial sale of
the Securities to the Buyer under this Agreement and (ii) any subsequent sale of the Securities by the Buyer, in each case, under
applicable securities or “Blue Sky” laws of the states of the United States in such states as is reasonably requested
by the Buyer from time to time, and shall provide evidence of any such action so taken to the Buyer.

 

(c) Listing. The Company shall
promptly secure the listing of all of the Company’s Common Stock listed upon each national securities exchange and automated
quotation system that requires an application by the Company for listing, if any, upon which shares of Common Stock are then listed
(subject to official notice of issuance) and shall maintain such listing, so long as any other shares of Common Stock shall be
so listed. The Company shall use its commercially reasonable efforts to maintain the Common Stock’s listing on the Principal
Market. Neither the Company nor any of its Subsidiaries shall take any action that would be reasonably expected to result
in the delisting or suspension of the Common Stock on the Principal Market, unless the Common Stock is immediately thereafter traded
on the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market, the NASDAQ Capital Market, or the OTCQB or OTCQX
market places of the OTC Markets. The Company shall pay all fees and expenses in connection with satisfying its obligations
under this Section.

 

(d) Limitation on Short Sales and Hedging
Transactions. The Buyer agrees that beginning on the date of this Agreement and ending on the date of termination of
this Agreement as provided in Section 11(k), the Buyer and its agents, representatives and affiliates shall not in any manner
whatsoever enter into or effect, directly or indirectly, any (i) “short sale” (as such term is defined in Section
242.200 of Regulation SHO of the 1934 Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position
with respect to the Common Stock.

 

(e) Issuance of Commitment Shares. In
connection with the Commencement, the Company shall issue to the Buyer in one or more tranches, at the sole discretion of Buyer,
as consideration for the Buyer entering into this Agreement such number of shares of Common Stock representing a dollar amount
equal to $230,167 based on a per share price equal to the Purchase Price on each of the dates that Buyer agrees to accept all
or part of such shares of Common Stock (the “Commitment Shares”). The Commitment Shares shall be transmitted
via DWAC within two (2) Business Days of the filing of the Prospectus Supplement and without any restrictive legend whatsoever
or prior sale requirement. If the Commitment Shares are not received within two (2) Business Days of the filing of the
Prospectus Supplement, the Company shall pay to Buyer all outstanding amounts in cash, including but not limited to, liquidated
damages of $5,000 per day until the Commitment Shares are delivered.

 

(f) Due Diligence. The Buyer
shall have the right, from time to time as the Buyer may reasonably deem appropriate, to perform reasonable due diligence on the
Company during normal business hours and subject to reasonable prior notice to the Company. The Company and its officers and
employees shall provide information and reasonably cooperate with the Buyer in connection with any reasonable request by the Buyer
related to the Buyer’s due diligence of the Company, including, but not limited to, any such request made by the Buyer in
connection with (i) the filing of the prospectus supplement described in Section 4(a) hereof and (ii) the Commencement; provided,
however, that at no time is the Company permitted to disclose material nonpublic information to the Buyer or breach any obligation
of confidentiality or non-disclosure to a third party or make any disclosure that could cause a waiver of attorney-client privilege. Each
party hereto agrees not to disclose any Confidential Information of the other party to any third party and shall not use the Confidential
Information of such other party for any purpose other than in connection with, or in furtherance of, the transactions contemplated
hereby. Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing party
and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by the other
party.

 

    8 

     

    

 

(g) Offering Restrictions. For a
period of ninety (90) days from the date hereof, the Company is prohibited from discussing, negotiating, agreeing to or entering
into any similar At The Market or equity line type of transactions.

 

	 	5.	TRANSFER AGENT INSTRUCTIONS. 

 

All of the Commitment Shares and Purchase
Shares to be issued under this Agreement shall be issued without any restrictive legend and as DWAC Shares unless the Buyer expressly
consents otherwise. The Company shall issue irrevocable instructions to the Transfer Agent, and any subsequent transfer agent,
to issue Common Stock in the name of the Buyer for the Purchase Shares (the “Irrevocable Transfer Agent Instructions”). The
Company warrants to the Buyer that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section
5, will be given by the Company to the Transfer Agent with respect to the Purchase Shares and that the Commitment Shares and the
Purchase Shares shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in
this Agreement and the Registration Rights Agreement.

 

	 	6.	CONDITIONS TO THE COMPANY’S RIGHT TO COMMENCE SALES OF SHARES OF COMMON STOCK UNDER THIS AGREEMENT. 

 

The right of the Company hereunder to commence
sales of the Purchase Shares is subject to the satisfaction of each of the following conditions on or before the Commencement Date
(the date that the Company may begin sales of Purchase Shares):

 

(a) The Buyer shall have executed each
of the Transaction Documents and delivered the same to the Company;

 

(b) The representations and warranties
of the Buyer shall be true and correct as of the Commencement Date as though made at that time (except for representations and
warranties that speak as of a specific date, which shall be true and correct in all material respects as of such specific date)
and the Buyer shall have performed, satisfied and complied in all material respects with the covenants and agreements required
by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Commencement Date, and the Company
shall have received a certificate, executed by a duly authorized officer of the Buyer, dated as of the Commencement Date, to the
foregoing effect; and

 

(c) The Prospectus Supplement shall have
been delivered to the Buyer and no stop order with respect to the registration statement covering the sale of shares to the Buyer
shall be pending or threatened by the SEC.

 

	 	7.	CONDITIONS TO THE BUYER’S OBLIGATION TO MAKE PURCHASES OF SHARES OF COMMON STOCK. 

 

The obligation of the Buyer to buy Purchase
Shares under this Agreement is subject to the satisfaction of each of the following conditions on or before the Commencement Date
(the date that the Company may begin sales of Purchase Shares) and once such conditions have been initially satisfied, there shall
be an ongoing obligation to continue to satisfy such conditions after the Commencement has occurred:

 

(a) The Company shall have executed each
of the Transaction Documents and delivered the same to the Buyer;

 

(b) The Company shall have issued to the
Buyer the Commitment Shares;

 

(c) The Common Stock shall be authorized
for quotation on the Principal Market, trading in the Common Stock shall not have been within the last 365 days suspended by the
SEC or the Principal Market, other than a general halt in trading in the Common Stock by the Principal Market under halt codes
indicating pending or released material news, and the Securities shall be approved for listing upon the Principal Market;

 

(d) The Buyer shall have received the opinion
of the Company’s legal counsel dated as of the Commencement Date in customary form and substance;

 

(e) The representations and warranties
of the Company shall be true and correct in all material respects (except to the extent that any of such representations and warranties
is already qualified as to materiality in Section 3 above, in which case, such representations and warranties shall be true and
correct without further qualification) as of the date of this Agreement and as of the Commencement Date as though made at that
time (except for representations and warranties that speak as of a specific date, which shall be true and correct in all material
respects as of such specific date) and the Company shall have performed, satisfied and complied in all material respects with
the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by
the Company at or prior to the Commencement Date. The Buyer shall have received a certificate, executed by the CEO, President
or CFO of the Company, dated as of the Commencement Date, to the foregoing effect in the form attached hereto as Exhibit A;

 

    9 

     

    

 

(f) The Board of Directors of the Company
or a duly authorized committee thereof shall have adopted resolutions substantially in the form attached hereto as Exhibit B
which shall be in full force and effect without any amendment or supplement thereto as of the Commencement Date;

 

(g) As of the Commencement Date, the Company
shall have reserved out of its authorized and unissued Common Stock, solely for the purpose of effecting future purchases of Purchase
Shares hereunder, 25,000,000 shares of Common Stock;

 

(h) The Irrevocable Transfer Agent Instructions,
in form acceptable to the Buyer shall have been delivered to and acknowledged in writing by the Company and the Buyer and have
been delivered to the Transfer Agent;

 

(i) The Company shall have delivered to
the Buyer a certificate evidencing the incorporation and good standing of the Company in the State of Delaware issued by the Secretary
of State of the State of Delaware as of a date within ten (10) Business Days of the Commencement Date;

 

(j) The Company shall have delivered to
the Buyer a secretary’s certificate executed by the Secretary of the Company, dated as of the Commencement Date, in the form
attached hereto as Exhibit C;

 

(k) The Shelf Registration Statement shall
have been declared effective under the 1933 Act by the SEC and no stop order with respect thereto shall be pending or threatened
by the SEC. The Company shall have prepared and delivered to the Buyer a final and complete form of prospectus supplement,
dated and current as of the Commencement Date, to be used in connection with any issuances of any Commitment Shares or Purchase
Shares to the Buyer, and to be filed by the Company within two (2) Business Days after the Commencement Date pursuant to Rule 424(b). The
Company shall have made all filings under all applicable federal and state securities laws necessary to consummate the issuance
of the Commitment Shares and the Purchase Shares pursuant to this Agreement in compliance with such laws;

 

(l) No Event of Default has occurred and
is continuing, or any event which, after notice and/or lapse of time, would become an Event of Default has occurred;

 

(m) On or prior to the Commencement Date,
the Company shall take all necessary action, if any, and such actions as reasonably requested by the Buyer, in order to render
inapplicable any control share acquisition, business combination, stockholder rights plan or poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the laws of the state
of its incorporation, other than Section 203 of the Delaware General Corporation Law, that is or could become applicable to the
Buyer as a result of the transactions contemplated by this Agreement, including, without limitation, the Company’s issuance
of the Securities and the Buyer’s ownership of the Securities; and

 

(n) The Company shall have provided the
Buyer with the information reasonably requested by the Buyer in connection with its due diligence requests made prior to, or in
connection with, the Commencement, in accordance with the terms of Section 4(f) hereof.

 

	 	8.	INDEMNIFICATION.

 

In consideration of the Buyer’s execution
and delivery of the Transaction Documents and acquiring the Securities hereunder and in addition to all of the Company’s
other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless the Buyer and
all of its affiliates, members, officers, directors, and employees, and any of the foregoing person’s agents or other representatives
(including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively,
the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties,
fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to
the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the
“Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (a)
any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or any other
certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation of
the Company contained in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby,
or (c) any cause of action, suit or claim brought or made against such Indemnitee and arising out of or resulting from the execution,
delivery, performance or enforcement of the Transaction Documents or any other certificate, instrument or document contemplated
hereby or thereby, other than with respect to Indemnified Liabilities which directly and primarily result from (A) a breach of
any of the Buyer’s representations and warranties, covenants or agreements contained in this Agreement, or (B) the gross
negligence, bad faith or willful misconduct of the Buyer or any other Indemnitee. To the extent that the foregoing undertaking
by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction
of each of the Indemnified Liabilities which is permissible under applicable law.

 

    10 

     

    

 

	 	9.	EVENTS OF DEFAULT.

 

An “Event of Default”
shall be deemed to have occurred at any time as any of the following events occurs:

 

(a) during any period in which the effectiveness
of any registration statement is required to be maintained pursuant to the terms of the Registration Rights Agreement, the effectiveness
of such registration statement lapses for any reason (including, without limitation, the issuance of a stop order) or is unavailable
to the Company for sale of all of the Registrable Securities (as defined in the Registration Rights Agreement) to the Buyer in
accordance with the terms of the Registration Rights Agreement, and such lapse or unavailability continues for a period of ten
(10) consecutive calendar days or for more than an aggregate of thirty (30) calendar days in any 365-day period, which is not in
connection with a post-effective amendment to any such registration statement or the filing of a new registration statement; provided,
however, that in connection with any post-effective amendment to such registration statement or filing of a new registration statement
that is required to be declared effective by the SEC, such lapse or unavailability may continue for a period of no more than thirty
(30) consecutive calendar days, which such period shall be extended for an additional thirty (30) calendar days if the Company
receives a comment letter from the SEC in connection therewith;

 

(b) the suspension from trading or failure
of the Common Stock to be listed on a Principal Market for a period of three (3) consecutive Business Days;

 

(c) the delisting of the Common Stock from
the Principal Market, and the Common Stock is not immediately thereafter trading on the New York Stock Exchange, the NYSE MKT,
the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market, the OTC Bulletin Board or the OTCQB marketplace
or OTCQX marketplace of the OTC Markets Group;

 

(d) the failure for any reason by the Transfer
Agent to issue Purchase Shares to the Buyer within three (3) Business days after the applicable Purchase Date that the Buyer is
entitled to receive;

 

(e) the Company’s breach of any representation
or warranty (as of the dates made), covenant or other term or condition under any Transaction Document if such breach would reasonably
be expected to have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably curable, only
if such breach continues uncured for a period of at least five (5) Business Days;

 

(f) if any Person commences a proceeding
against the Company pursuant to or within the meaning of any Bankruptcy Law;

 

(g) if the Company pursuant to or within
the meaning of any Bankruptcy Law; (A) commences a voluntary case, (B) consents to the entry of an order for relief against it
in an involuntary case, (C) consents to the appointment of a Custodian of it or for all or substantially all of its property, (D)
makes a general assignment for the benefit of its creditors or (E) becomes insolvent;

 

(h) a court of competent jurisdiction enters
an order or decree under any Bankruptcy Law that (A) is for relief against the Company in an involuntary case, (B) appoints a Custodian
of the Company or for all or substantially all of its property, or (C) orders the liquidation of the Company or any Subsidiary;

 

(i) if at any time after the Commencement
Date, the Exchange Cap is reached unless and until stockholder approval is obtained pursuant to Section 1(h) hereof. The Exchange
Cap shall be deemed to be reached at such time if, upon submission of a Purchase Notice or Additional Purchase Notice under this
Agreement, the issuance of such shares of Common Stock would exceed the number of shares of Common Stock which the Company may
issue under this Agreement without breaching the Company’s obligations under the rules or regulations of the Principal Market;

 

(j) a default by the Company of a material
term, covenant, warranty or undertaking of any agreement to which the Company is a party to; or

 

(k) failure of the Company to publicly
disclose within one business day any material default described in Section 9(j) above.

 

    11 

     

    

 

In addition to any other rights and remedies under applicable
law and this Agreement, including the Buyer termination rights under Section 11(k) hereof, so long as an Event of Default has occurred
and is continuing, or if any event which, after notice and/or lapse of time, would become an Event of Default, has occurred and
is continuing, or so long as the Closing Bid Price is below the Floor Price, the Company may not require and the Buyer shall not
be obligated to purchase any shares of Common Stock under this Agreement. If pursuant to or within the meaning of any Bankruptcy
Law, the Company commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed
for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its
creditors, (any of which would be an Event of Default as described in Sections 9(f), 9(g) and 9(h) hereof) this Agreement shall
automatically terminate without any liability or payment to the Company without further action or notice by any Person. No
such termination of this Agreement under Section 11(k)(i) shall affect the Company’s or the Buyer’s obligations under
this Agreement with respect to pending purchases and the Company and the Buyer shall complete their respective obligations with
respect to any pending purchases under this Agreement.

 

In addition to any other rights and remedies under applicable
law and this Agreement, including the Buyer termination rights under Section 11(k) hereof, upon the occurrence of an Event of Default,
the Company will pay to Buyer as liquidated damages and not as a penalty the sum of $250,000 in cash, shares or a combination thereof,
at the election of Buyer. If paid in shares, the shares will be valued at the Purchase Price in effect on the day Buyer notifies
the Company of its election to receive such shares.

 

	 	10.	CERTAIN DEFINED TERMS.

 

For purposes of this Agreement, the following
terms shall have the following meanings:

 

(a) “1933 Act” means
the Securities Act of 1933, as amended.

 

(b) Intentionally Omitted.

 

(c) “Additional Purchase Amount”
means, with respect to any particular Additional Purchase Notice, the portion of the Available Amount to be purchased by the Buyer
pursuant to Section 1(c) hereof pursuant to a valid Additional Purchase Notice which requires the Buyer to buy the additional Purchase
Shares.

 

(d) “Additional Purchase Date”
means, with respect to any Additional Purchase made hereunder, the same Business Day following the receipt by the Buyer of a valid
Additional Purchase Notice that the Buyer is to buy Purchase Shares pursuant to Section 1(c) hereof, provided such valid Additional
Purchase Notice is delivered no later than 9:00 a.m. Eastern Time on such Business Day. If delivered later than 9:00 a.m. Eastern
Time, the Additional Purchase Date will be the next Business Day, unless waived by Buyer, in its sole discretion.

 

(e) Intentionally Omitted.

 

(f) Intentionally Omitted.

 

(g) “Additional Purchase Price”
the lowest intra-day bid price of the Common Stock on the Additional Purchase Date.

 

(h) “Additional Purchase Share
Estimate” means the number of shares of Common Stock that the Company has in its sole discretion irrevocably instructed
its Transfer Agent to issue to the Buyer via the Depository Trust Company (“DTC”) Fast Automated Securities
Transfer Program in connection with a Additional Purchase Notice pursuant to Section 1(c) hereof and issued to the Buyer’s
or its designee’s balance account with DTC through its Deposit Withdrawal At Custodian (DWAC) system on the Additional Purchase
Date (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split
or other similar transaction).

 

(i) “Additional Purchase Share
Volume Maximum” means a number of shares of Common Stock traded on the Principal Market during normal trading hours on
the Additional Purchase Date equal to: (i) the Additional Purchase Share Estimate, divided by (ii) the Additional Purchase Share
Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock
split or other similar transaction).

 

(j) “Available Amount”
means Three Million Fify Seven Thousand One Hundred Dollars ($3,057,100) in the aggregate which amount shall be reduced by the
Purchase Amount (including the Initial Purchase) each time the Buyer purchases shares of Common Stock pursuant to Section 1 hereof.

 

(k) “Bankruptcy Law”
means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.

 

    12 

     

    

 

(l) “Business Day” means
any day on which the Principal Market is open for trading during normal trading hours (i.e., 9:30 a.m. to 4:00 p.m. Eastern Time),
including any day on which the Principal Market is open for trading for a period of time less than the customary time.

 

(m) “Closing Bid Price”
means the closing bid price for the Common Stock on the Principal Market as reported by the Principal Market.

 

(n) “Confidential Information”
means any information disclosed by either party to the other party, either directly or indirectly, in writing, orally or by inspection
of tangible objects (including, without limitation, documents, prototypes, samples, protocols, development plans, commercialization
plans, compounds, formulations, preclinical study and clinical trial results, plant and equipment), which is designated as “Confidential,”
“Proprietary” or some similar designation. Information communicated orally shall be considered Confidential Information
if such information is expressly identified as Confidential Information at the time of such initial disclosure and confirmed in
writing as being Confidential Information within ten (10) Business Days after the initial disclosure. Confidential Information
may also include information disclosed to a disclosing party by third parties. Confidential Information shall not, however, include
any information which (i) was publicly known and made generally available in the public domain prior to the time of disclosure
by the disclosing party; (ii) becomes publicly known and made generally available after disclosure by the disclosing party to the
receiving party through no action or inaction of the receiving party; (iii) is already in the possession of the receiving party
at the time of disclosure by the disclosing party as shown by the receiving party’s files and records immediately prior to
the time of disclosure; (iv) is obtained by the receiving party from a third party without a breach of such third party’s
obligations of confidentiality; (v) is independently developed by the receiving party without use of or reference to the disclosing
party’s Confidential Information, as shown by documents and other competent evidence in the receiving party’s possession;
or (vi) is required by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party
prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information
from public disclosure.

 

(o) “Custodian” means
any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

 

(p) “DTC” means the
Depository Trust Company, or any successor performing substantially the same function for the Company.

 

(q) “DWAC Shares” means
shares of Common stock that are (i) issued in electronic form, (ii) freely tradable and transferable and without restriction on
resale, and (iii) timely credited by the Company to the Buyer or its designee’s specified Deposit of Withdrawal at Custodian
(“DWAC”) account with DTC under its Fast Automatic Securities Transfer (“FAST”) Program or any similar
program hereafter adopted by DTC performing substantially the same function.

 

(r) “Market Price” shall
mean, (i) shall mean, (i) from 9:30am to 4:00pm Eastern Time of the regular session of any trading day, lowest intra-day bid price
or (ii) if after the close of the regular session on any trading day, then such trading day’s Closing Bid Price.

 

(s) “Maturity Date”
means the date that is twenty-four (24) months from the Commencement Date.

 

(t) “Person” means an
individual or entity including any limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated
organization and a government or any department or agency thereof.

 

(u) “Principal Market”
means the Nasdaq Global Market; provided however, that in the event the Company’s Common Stock is ever listed or traded on
the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market, the Nasdaq Global Market, the NASDAQ Capital Market,
the OTC Bulletin Board or either of the OTCQB Marketplace or the OTCQX marketplace of the OTC Markets Group, then the “Principal
Market” shall mean such other market or exchange on which the Company’s Common Stock is then listed or traded.

 

(v) “Purchase Amount”
means, with respect to any particular purchase made hereunder, the portion of the Available Amount to be purchased by the Buyer
pursuant to Section 1 hereof as set forth in a valid Purchase Notice or Additional Purchase Notice which the Company delivers to
the Buyer.

 

(w) “Purchase Date”
means with respect to any Regular Purchase made hereunder, the Business Day of receipt by the Buyer of a valid Purchase Notice
that the Buyer is to buy Purchase Shares pursuant to Section 1(b) hereof, provided such valid Purchase Notice is delivered no later
than 9:00 a.m. Eastern Time on such Business Day. If delivered later than 9:00 a.m. Eastern Time, the Purchase Date will be the
next Business Day, unless waived by Buyer, in its sole discretion.

 

(x) “Purchase Notice”
shall mean an irrevocable written notice from the Company to the Buyer directing the Buyer to buy Purchase Shares pursuant to Section
1(b) hereof as specified by the Company therein at the applicable Purchase Price on the Purchase Date.

 

    13 

     

    

 

(y) “Purchase Price”
shall mean the Market Price (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split,
reverse stock split or other similar transaction).

 

(z) “SEC” means the
United States Securities and Exchange Commission.

 

(aa) “Transfer Agent”
means the transfer agent of the Company as set forth in Section 11(f) hereof or such other person who is then serving as the transfer
agent for the Company in respect of the Common Stock.

 

	 	11.	MISCELLANEOUS. 

 

(a) Governing Law; Jurisdiction; Jury
Trial. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to
the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any action,
suit or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or
proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or
certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then, the prevailing party
in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs
and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. IN ANY ACTION, SUIT,
OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO
THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL
BY JURY.

 

(b) Counterparts. This Agreement
may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf (or
other electronic reproduction) signature shall be considered due execution and shall be binding upon the signatory thereto with
the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction) signature.

 

(c) Headings. The headings
of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

(d) Severability. If any provision
of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the
validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision
of this Agreement in any other jurisdiction.

 

(e) Entire Agreement. This
Agreement and the Registration Rights Agreement supersede all other prior oral or written agreements between the Buyer, the Company,
their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement, the other
Transaction Documents and the instruments referenced herein contain the entire understanding of the parties with respect to the
matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Buyer makes
any representation, warranty, covenant or undertaking with respect to such matters. The Company acknowledges and agrees that
is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly set
forth in this Agreement.

 

(f) Notices. Any notices, consents
or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed
to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile (provided confirmation
of transmission is mechanically or electronically generated and kept on file by the sending party); (iii) upon receipt, when sent
by electronic message (provided the recipient responds to the message and confirmation of both electronic messages are kept on
file by the sending party); or (iv) one (1) Business Day after timely deposit with a nationally recognized overnight delivery service,
in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications shall
be:

 

    14 

     

    

 

If to the Company:

 

Immune Pharmaceuticals Inc.

430 East 29th Street, Suite 940

New York, NY 10016

Telephone:      646-440-9310

Facsimile:         917-398-1922

Attention:        Daniel
Teper, Chief Executive Officer

Email:                Daniel.teper@immunepharma.com

 

With a copy (which shall not constitute
notice) to:

 

Sheppard Mullin Richter & Hampton LLP

30 Rockefeller Plaza, New York, NY 10112

Telephone:      212-634-3031

Facsimile:         212-655-1729

Attention:        Richard
A. Friedman, ESQ

Email:                Rafriedman@sheppardmullin.com

 

If to the Buyer:

 

HLHW IV, LLC

708 Third Avenue, 6th Floor

New York, NY 10017

Telephone:       [REQUIRES
COMPLETION]

Facsimile:          [REQUIRES
COMPLETION]

Attention:         [REQUIRES
COMPLETION]

Email:                 [REQUIRES
COMPLETION].com

 

With a copy to (which shall not constitute
delivery to the Buyer):

 

Grushko & Mittman, P.C.

515 Rockaway Avenue

Valley Stream, NY 11581

Telephone:      212-697-9500

Facsimile:         212-697-3575

Attention:        Barbara
R. Mittman, Esq.

Email:                barbara@grushkomittman.com

 

If to the Transfer Agent:

VStock Transfer, LLC

18 Lafayette Place

Woodmere, NY 11598

Telephone:      212-828-8436

Facsimile:         646-536-3179

Attention:        Allison
Niccolls

Email:                Allison@vstocktransfer.com

 

or at such other address and/or facsimile number and/or to the
attention of such other person as the recipient party has specified by written notice given to each other party at least one (1)
Business Day prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such
notice, consent or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing
the time, date, and recipient facsimile number, (C) electronically generated by the sender’s electronic mail containing the
time, date and recipient email address or (D) provided by a nationally recognized overnight delivery service, shall be rebuttable
evidence of receipt in accordance with clause (i), (ii), (iii) or (iv) above, respectively.

 

    15 

     

    

 

(g) Successors and Assigns. This
Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns. The Company
shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Buyer, including
by merger or consolidation; provided, however, that any transaction, whether by merger, reorganization, restructuring, consolidation,
financing or otherwise, whereby the Company remains the surviving entity immediately after such transaction, shall not be deemed
a succession or assignment. The Buyer may not assign its rights or obligations under this Agreement.

 

(h) No Third Party Beneficiaries. This
Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for
the benefit of, nor may any provision hereof be enforced by, any other person.

 

(i) Further Assurances. Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(j) Termination. This Agreement
may be terminated only as follows:

 

(i) By the Buyer any time an
Event of Default exists without any liability or payment to the Company. However, if pursuant to or within the meaning of any Bankruptcy
Law, the Company commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed
for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its
creditors, (any of which would be an Event of Default as described in Sections 9(f), 9(g) and 9(h) hereof) this Agreement shall
automatically terminate without any liability or payment to the Company without further action or notice by any Person. No
such termination of this Agreement under this Section 11(k)(i) shall affect the Company’s or the Buyer’s obligations
under this Agreement with respect to pending purchases and the Company and the Buyer shall complete their respective obligations
with respect to any pending purchases under this Agreement.

 

(ii) In the event that the
Commencement shall not have occurred by November 15, 2016, the Company shall have the option to terminate this Agreement for any
reason or for no reason without any liability whatsoever of either party to the other party under this Agreement.

 

(iii) In the event that the
Commencement shall not have occurred within ten (10) Business Days of the date of this Agreement, due to the failure to satisfy
any of the conditions set forth in Sections 6 and 7 above with respect to the Commencement, either party shall have the option
to terminate this Agreement at the close of business on such date or thereafter without liability of either party to any other
party except as described herein; provided, however, that the right to terminate this Agreement under this Section 11(k)(iii) shall
not be available to either party if such failure to satisfy any of the conditions set forth in Sections 6 and 7 is the result of
a breach of this Agreement by such party or the failure of any representation or warranty of such party included in this Agreement
to be true and correct in all material respects. A termination fee pursuant to this Paragraph (j)(iii) of $250,000 in cash, shares
or a combination thereof, at Buyer’s election with such shares to be valued at the Purchase Price, will be immediately payable
by the Company to Buyer.

 

(iv) At any time after the
Commencement Date, the Company shall have the option to terminate this Agreement for any reason or for no reason by delivering
notice (a “Company Termination Notice”) to the Buyer electing to terminate this Agreement without any liability
whatsoever of either party to the other party under this Agreement except that the Company must transmit to Buyer a Termination
Fee of $250,000 in cash or shares, at Buyer’s election with such shares to be valued at the Purchase Price, within two (2)
Business Days following delivery of the Company Termination Notice. The Company Termination Notice shall not be effective
until one (1) Business Day after it has been received by the Buyer. If the Termination Fee is not received within two (2) Business
Days following delivery of the Company Termination Notice, the Company will pay the Buyer as liquidated damages of $5,000 per day
in cash, shares or a combination thereof, at Buyer’s election with such shares to be valued at the Purchase Price, for each
day of delay in payment of the Termination Fee together with any applicable legal fees.

 

(v) This Agreement shall automatically
terminate on the date that the Company sells and the Buyer purchases the full Available Amount as provided herein, without any
action or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement.

 

(vi) If by the Maturity Date
for any reason or for no reason the full Available Amount under this Agreement has not been purchased as provided for in Section
1 of this Agreement, this Agreement shall automatically terminate on the Maturity Date, without any action or notice on the part
of any party and without any liability whatsoever of any party to any other party under this Agreement.

 

    16 

     

    

 

Except as set forth in Sections
11(j)(i) (in respect of an Event of Default under Sections 9(f), 9(g) and 9(h)), 11(j)(v) and 11(j)(vi), any termination of this
Agreement pursuant to this Section 11(j) shall be effected by written notice from the Company to the Buyer, or the Buyer to the
Company, as the case may be, setting forth the basis for the termination hereof. The representations and warranties of the
Company and the Buyer contained in Sections 2, 3 and 5 hereof, the indemnification provisions set forth in Section 8 hereof and
the agreements and covenants set forth in Sections 4(e) and 11, shall survive the Commencement and any termination of this Agreement. No
termination of this Agreement shall affect the Company’s or the Buyer’s rights or obligations (i) under the Registration
Rights Agreement which shall survive any such termination in accordance with its terms or (ii) under this Agreement with respect
to pending purchases and the Company and the Buyer shall complete their respective obligations with respect to any pending purchases
under this Agreement.

 

(k) No Financial Advisor, Placement
Agent, Broker or Finder. The Company represents and warrants to the Buyer that it has not engaged any financial advisor,
placement agent, broker or finder in connection with the transactions contemplated hereby. The Buyer represents and warrants
to the Company that it has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions
contemplated hereby. Each party shall be responsible for the payment of any fees or commissions, if any, of any financial
advisor, placement agent, broker or finder engaged by such party relating to or arising out of the transactions contemplated hereby. Each
party shall pay, and hold the other party harmless against, any liability, loss or expense (including, without limitation, attorneys’
fees and out of pocket expenses) arising in connection with any such claim.

 

(l) No Strict Construction. The
language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no
rules of strict construction will be applied against any party.

 

(m) Failure or Indulgence Not Waiver. No
failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single
or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power
or privilege.

*      *      *      *    
  * 

  

    17 

     

    

 

 

IN WITNESS WHEREOF, the Buyer and
the Company have caused this Common Stock Purchase Agreement to be duly executed as of the date first written above.

 

	 	 	 	 
	 	THE COMPANY:
	 	 
	 	IMMUNE PHARMACEUTICALS INC.
	 	 	 
	 	By:	 	
        Daniel G. Teper

	 	Name:	 	Daniel G. Teper
	 	Title:	 	CEO
	 	
         

         

	 	BUYER:
	 	 
	 	HLHW IV, LLC
	 	 	 
	 	By:	 	
        J. Miller

	 	Name:	 	J. Miller 
	 	Title: 	 	 

  

    18 

     

    

 

 

SCHEDULES 

 

	 	 	 
	Schedule 3(a)	 	Subsidiaries
	Schedule 3(c)	 	Capitalization
	Schedule 3(e)	 	Conflicts
	Schedule 3(f)	 	1934 Act Filings
	Schedule 3(g)	 	Material Changes
	Schedule 3(h)	 	Litigation
	 	 	 
	 	 	 
	 	 	 

EXHIBITS 

 

	 	 	 
	Exhibit A	 	Form of Officer’s Certificate
	Exhibit B	 	Form of Resolutions of Board of Directors of the Company
	Exhibit C              	 	Form of Secretary’s Certificate

 

    19 

     

    

SCHEDULE 3.1(a)

 

List of Subsidiaries

 

 

 

	Name of Entity	Jurisdiction of Incorporation	Ownership
	
        Immune Pharmaceuticals Ltd.

         

        Cytovia Inc.

         

        Maxim Pharmaceuticals, Inc.

         

        Immune Pharmaceuticals Corp

         
	
        Israel

         

        Delaware

         

        Delaware

         

        Delaware

         
	
        100%

         

        100%

         

        100%

         

        100%

 

 

    20 

     

    

 

 

SCHEDULE 3(c)

 

Capitalization

 

None 

 

2015 Equity Incentive Plan -15,000,000
Shares

 

    21 

     

    

 

Schedule 3(e)

 

None

    22 

     

    

 

 

SCHEDULE 3.1(h)

 

SEC Reports 

 

None.

 

10-K due on or before March 31, 2017.

 

 

 

    23 

     

    

 

 

SCHEDULE 3.1(i)

 

Material Changes

 

None

 

    24 

     

    

 

 

SCHEDULE 3(g)

 

Litigation

 

 

 

As disclosed in the Q-3, 2016 Form 10-Q.

 

    25 

     

    

 

 

EXHIBIT A

 

FORM OF OFFICER’S CERTIFICATE 

 

This Officer’s Certificate (“Certificate”)
is being delivered pursuant to Section 7(e) of that certain Common Stock Purchase Agreement dated as of [REQUIRES COMPLETION],
2016 (the “Common Stock Purchase Agreement”), by and between IMMUNE PHARMACEUTICALS INC., a Delaware
corporation (the “Company”), and HLHW IV, LLC, a Delaware limited liability company (the “Buyer”). Terms
used herein and not otherwise defined shall have the meanings ascribed to them in the Common Stock Purchase Agreement.

 

The undersigned, [REQUIRES COMPLETION],
[REQUIRES COMPLETION] of the Company, hereby certifies as follows:

 

1. I am the [REQUIRES COMPLETION]
of the Company and make the statements contained in this Certificate in my capacity as such;

 

2. The representations and
warranties of the Company are true and correct in all material respects (except to the extent that any of such representations
and warranties is already qualified as to materiality in Section 3 of the Common Stock Purchase Agreement, in which case, such
representations and warranties are true and correct without further qualification) as of the date when made and as of the Commencement
Date as though made at that time (except for representations and warranties that speak as of a specific date);

 

3. The Company has performed,
satisfied and complied in all material respects with covenants, agreements and conditions required by the Transaction Documents
to be performed, satisfied or complied with by the Company at or prior to the Commencement Date.

 

4. The Company has not taken
any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor does the Company
or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy
or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become due.

 

IN WITNESS WHEREOF, I have hereunder signed
my name on this [REQUIRES COMPLETION] day of [REQUIRES COMPLETION], 2016.

 

	 	 
	 	
 

	 	Name:
	 	Title:

 

The undersigned as Secretary of IMMUNE
PHARMACEUTICALS INC., a Delaware corporation, hereby certifies that [REQUIRES COMPLETION] is the duly elected, appointed, qualified
and acting [REQUIRES COMPLETION] of the Company and that the signature appearing above is his/her genuine signature.

 

	 	 
	 	
 

        Secretary

         

 

    26 

     

    

 

EXHIBIT B

 

FORM OF COMPANY RESOLUTIONS

FOR SIGNING PURCHASE AGREEMENT

 

WHEREAS, management has reviewed with the
Board of Directors the background, terms and conditions of the transactions subject to the Common Stock Purchase Agreement (the
“Purchase Agreement”) by and between the Company and HLHW IV, LLC (“HLHW”), including all
materials terms and conditions of the transactions subject thereto, providing for the purchase by HLHW of up to Three Million Fifty
Seven Thousand One Hundred Dollars ($3,057,100) of the Company’s common stock, par value $0.0001 per share (the “Common
Stock”); and

 

Transaction Documents

 

NOW, THEREFORE, BE IT RESOLVED, that the
transactions described in the Purchase Agreement are hereby approved and the Chief Executive Officer, the Principal Financial Officer
of the Company (the “Authorized Officers”) are severally authorized to execute and deliver the Purchase Agreement
in substantially the form attached as Exhibit A hereto, and any other agreements or documents contemplated thereby including,
without limitation, a registration rights agreement (the “Registration Rights Agreement”) in substantially the
form attached as Exhibit B hereto providing for the registration of the issuance and/or sale of shares of Common Stock to
HLHW under the Purchase Agreement, with such amendments, changes, additions and deletions as the Authorized Officers may deem to
be appropriate and approve on behalf of the Company, such approval to be conclusively evidenced by the signature of an Authorized
Officer thereon; and

 

FURTHER RESOLVED, that the terms and provisions
of the Form of Transfer Agent Instructions (the “Instructions”) in substantially the form attached as Exhibit
C hereto are hereby approved and the Authorized Officers are authorized to execute and deliver the Instructions (pursuant to
the terms of the Purchase Agreement), with such amendments, changes, additions and deletions as the Authorized Officers may deem
appropriate and approve on behalf of the Company, such approval to be conclusively evidenced by the signature of an Authorized
Officer thereon; and

 

Issuance of Common Stock

 

FURTHER RESOLVED, that the Company is hereby
authorized to issue shares of Common Stock upon the purchase of Purchase Shares from time to time with an aggregate purchase price
of up to $10,000,000 under the Purchase Agreement, at a price per share equal to or greater than $[REQUIRES COMPLETION], in accordance
with the terms of the Purchase Agreement, provided that the number of shares of Common Stock issued pursuant to the Purchase
Agreement (including all Purchase Shares and Additional Purchase Shares) (the “Purchase Shares” and “Additional
Purchase Shares”, the “HLHW Shares”) shall not exceed 19.99% of the Company’s outstanding shares
of Common Stock as of the date hereof without the affirmative consent of the stockholders; and that, upon issuance of the Purchase
Shares pursuant to the Purchase Agreement, including payment therefor, the Purchase Shares will be duly authorized, validly issued,
fully paid and non-assessable; and

 

FURTHER RESOLVED, that the Company is authorized
to, and hereby does, reserve out of its authorized but unissued shares of Common Stock the maximum number of shares of Common Stock that
is issuable to HLHW under the Purchase Agreement, subject to automatic adjustment from time to time as Purchase Shares are sold
to HLHW; and

 

    27 

     

    

 

Prospectus Supplement

 

FURTHER RESOLVED, that the Authorized Officers
are hereby authorized, in the name and on behalf of the Company:

 

	 	1.	to prepare, execute and file with the Securities and Exchange Commission (the “SEC”) such prospectus supplements, including any preliminary or final prospectus supplement, to the Company’s Registration Statement on Form S-3 on file with the SEC (File No. 333-198647) (the “Shelf S-3 Registration Statement”) and the prospectus included therein and such additional documents, including any free writing prospectuses, as the Authorized Officer so acting may determine, in his or her sole discretion, to be necessary, appropriate or desirable in connection with the transactions pursuant to the Purchase Agreement, such determination to be conclusively evidenced by the execution and filing of such prospectus supplements, prospectuses or additional documents; and 

 

	 	2.	to prepare, execute and file with the SEC one or more additional registration statements on Form S-3 relating to the registration under the Securities Act of any Purchase Shares that were not registered pursuant to the Shelf S-3 Registration Statement, to the extent required pursuant to the Registration Rights Agreement; and 

 

Proceeds

 

FURTHER RESOLVED, that following the sale
of the Purchase Shares, it is the intention of the Company (a) to continue to be primarily engaged in the business of drug
discovery, development and commercialization (the “Company Business”), rather than in the business of
investing or reinvesting in, or owning, holding or trading securities; (b) to employ the proceeds of the sale of the Purchase Shares
in the Company Business; and (c) as soon as is reasonably possible, but in any event within one year from the closing of any sale
of Purchase Shares, to have invested the proceeds of such sale not theretofore expended in the Company Business in a manner consistent
with their preservation for future use in the Company Business and with the Company not being an “investment company”
as defined in the Investment Company Act of 1940, as amended; and

 

FURTHER RESOLVED, that, of the consideration
to be received by the Company for the Purchase Shares, an amount equal to the par value per share sold is hereby determined to
be capital to be allocated on the books of the Company to the Common Stock capital account, and the difference between the aggregate
amount so allocated and the aggregate consideration received for the Purchase Shares shall be credited on the books of the Company
as additional paid-in capital for purposes of financial reporting and as surplus for purposes of the General Corporation Law of
the State of Delaware; and

 

Transfer Agent and Registrar

 

FURTHER RESOLVED, that for the purpose
of the original issuance of the HLHW Shares in accordance with the foregoing resolutions, American Stock Transfer & Trust Company
(the “Transfer Agent”) is hereby authorized to issue, countersign and register such certificates as may be required
for such issuance and to deliver such stock certificates in accordance with the instructions of an Authorized Officer, or to cause
any such HLHW Shares to be delivered through electronic book entry; and that if the Transfer Agent requires a prescribed form of
preambles or resolutions relating to the foregoing, each such preamble or resolution is hereby adopted by the Board, and the Secretary
or any Assistant Secretary of the Company is hereby authorized to certify the adoption of any such preamble or resolution and to
insert all such preambles and resolutions in the minute book of the Company immediately following this resolution; and

 

Listing of Shares on the Nasdaq Capital
Market

 

FURTHER RESOLVED, that the Authorized Officers,
with the assistance of counsel be, and each of them hereby is, authorized and directed to take all necessary steps and do all other
things necessary and appropriate to effect the listing of the HLHW Shares on the Nasdaq Capital Market including, if applicable,
the filing of a Notification Form for Listing of Additional Shares and the payment of any required fees; and

 

    28 

     

    

 

State Securities Laws

 

FURTHER RESOLVED, that it is desirable
and in the best interests of the Company that its Common Stock be qualified or registered for sale, to the extent required by law,
in various states and other jurisdictions, and that the Authorized Officers are each hereby authorized and directed to determine
the states and other jurisdictions in which appropriate action shall be taken to (i) qualify or register for sale all or such part
of such Common Stock and (ii) register the Company as a dealer or broker; that the Authorized Officers be, and hereby are, authorized
to perform on behalf of the Company any and all such acts as the officer so acting may deem necessary or advisable in order to
comply with the applicable laws of any such states and other jurisdictions, and in connection therewith to execute, affix the Company’s
seal to and file all requisite papers and documents, including, without limitation, applications, resolutions, reports, surety
bonds, irrevocable consents and appointments of attorneys for service of process; and that execution by any of the Authorized Officers
of any such paper or document or the doing by any of the Authorized Officers of any act in connection with the foregoing matters
shall conclusively establish the authority of the officers so acting therefor from the Company and the approval and ratification
by the Company of the papers and documents so executed and the action so taken; and

 

FURTHER RESOLVED, that if the securities
or “blue sky” laws of any of the states or other jurisdictions in which any of the Authorized Officers deem it necessary
or advisable to qualify or register for sale all or part of the Common Stock or to register the Company as a dealer or broker,
or any authority administering such laws, requires a prescribed form of preambles or resolutions relating to such sale or to any
application, statement, instrument or other document connected therewith, each such preamble or resolution is hereby adopted by
the Board, and the Secretary or any Assistant Secretary of the Company is hereby authorized to certify the adoption of any such
preamble or resolution to any party who may so request and to insert all such preambles and resolutions in the minute book of the
Company immediately following these resolutions; and

 

Approval of Actions

 

FURTHER RESOLVED, that the Company be and
hereby is authorized to enter into any and all amendments to its agreements with, or obtain any and all waivers from, (i) the holders
of any outstanding securities of the Company and (ii) any other entity, as may be necessary or desirable to effectuate the events
and transactions contemplated by these resolutions; and

 

FURTHER RESOLVED, that, without limiting
the foregoing, the Authorized Officers are, and each of them hereby is, authorized and directed to proceed on behalf of the Company
and to take all such steps as deemed necessary or appropriate, with the advice and assistance of counsel, to cause the Company
to consummate the agreements referred to herein and to perform its obligations under such agreements; and

 

FURTHER RESOLVED, that the Authorized Officers
be, and each of them hereby is, authorized, empowered and directed on behalf of and in the name of the Company, to take or cause
to be taken all such further actions and to execute and deliver or cause to be executed and delivered all such further agreements,
amendments, documents, certificates, reports, schedules, applications, notices, letters and undertakings and to incur and pay all
such fees and expenses as in their judgment shall be necessary, proper or desirable to carry into effect the purpose and intent
of any and all of the foregoing resolutions, and that all actions heretofore taken by any officer or director of the Company in
connection with the transactions contemplated by the agreements described herein are hereby approved, ratified and confirmed in
all respects.

 

    29 

     

    

 

EXHIBIT C

 

FORM OF SECRETARY’S CERTIFICATE

 

This Secretary’s Certificate (the
“Certificate”) is being delivered pursuant to Section 7(k) of that certain Common Stock Purchase Agreement dated
as of [REQUIRES COMPLETION], 2016 (the “Common Stock Purchase Agreement”), by and between IMMUNE PHARMACEUTICALS,
INC., a Delaware corporation (the “Company”) and HLHW IV, LLC, a Delaware limited liability company
(the “Buyer”), pursuant to which the Company may sell to the Buyer up to Three Million Fifty Seven Thousand
One Hundred Dollars ($3,057,100) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”). Terms
used herein and not otherwise defined shall have the meanings ascribed to them in the Common Stock Purchase Agreement.

 

The undersigned, [REQUIRES COMPLETION],
Secretary of the Company, hereby certifies as follows in his capacity as such:

 

1. I am the Secretary of the
Company and make the statements contained in this Secretary’s Certificate.

 

2. Attached hereto as Exhibit
A and Exhibit B are true, correct and complete copies of the Company’s bylaws (“Bylaws”) and Certificate
of Incorporation (“Certificate of Incorporation”), respectively, in each case, as amended through the date hereof,
and no action has been taken by the Company, its directors, officers or stockholders, in contemplation of the filing of any further
amendment relating to or affecting the Bylaws or the Certificate of Incorporation.

 

3. Attached hereto as Exhibit
C are true, correct and complete copies of the resolutions duly adopted by the Board of Directors of the Company on [REQUIRES COMPLETION],
2016 at which a quorum was present and acting throughout. Such resolutions have not been amended, modified or rescinded and
remain in full force and effect and such resolutions are the only resolutions adopted by the Company’s Board of Directors,
or any committee thereof, or the stockholders of the Company relating to or affecting (i) the entering into and performance of
the Common Stock Purchase Agreement, or the issuance, offering and sale of the Purchase Shares and (ii) and the performance of
the Company of its obligation under the Transaction Documents as contemplated therein.

 

4. As of the date hereof, the
authorized, issued and reserved capital stock of the Company is as set forth on Exhibit D hereto.

 

IN WITNESS WHEREOF, I have hereunder
signed my name on this [REQUIRES COMPLETION] day of [REQUIRES COMPLETION].

 

	 	 
	 	
 

	 	[REQUIRES COMPLETION], Secretary

 

The undersigned as [REQUIRES COMPLETION] of IMMUNE PHARMACEUTICALS
INC., a Delaware corporation, hereby certifies that [REQUIRES COMPLETION] is the duly elected, appointed, qualified and acting
Secretary of the Company, and that the signature appearing above is his/her genuine signature.

 

	 	 
	 	 
	 	
         

         

 

    30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]